REVIEW ON LIPID NANOPARTICLES OF TAZAROTENE FOR TREATMENT OF PSORIASIS

Psoriasis is a chronic autoimmune inflammatory skin disorder characterized by accelerated keratinocyte proliferation and dysregulated immune responses, leading to visible skin lesions such as erythematous plaques and scales. Normally, skin cells mature and shed over a month; however, in psoriasis this process occurs within 3–4 days, causing cellular accumulation on the skin surface. Globally, psoriasis affects approximately 2–3% of the population, with notable gender and age variations, including a higher prevalence among men in India. The disease presents in multiple forms, including plaque, inverse, guttate, pustular, and erythrodermic psoriasis, each differing in severity, distribution, and clinical features. Plaque psoriasis is the most common type, accounting for 80–90% of cases. Psoriasis is associated with significant complications such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, psychological disorders, and increased cancer risk. Clinical manifestations commonly include thick scaly plaques,